Abstract: RESULTS:
PA/
I38N in A(H1N1)pdm09 and
PA/
I38R in A(H3N2) were newly identified as treatment-emergent substitutions in the CAPSTONE-2 study.
Abstract: The
I38N substitution conferred reduced susceptibility by 24-fold, whereas replicative capacity of the
I38N-substituted virus was impaired compared with the wild-type.
Abstract: The
I38R-substituted virus was not viable in cell culture.
Method: In the CAPSTONE-2 study, next-generation sequencing (NGS) was also employed with the samples meeting the following criteria: (a) subjects shedding A(H3N2) viruses with
PA/
I38T substitution, (b) virology data (viral titer and RNA) are available at days 1, 2, 3 or 4, and